International Assets Investment Management LLC Acquires 5,595 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

International Assets Investment Management LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7,880.3% during the fourth quarter, HoldingsChannel reports. The firm owned 5,666 shares of the company’s stock after buying an additional 5,595 shares during the quarter. International Assets Investment Management LLC’s holdings in Neurocrine Biosciences were worth $747,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Headinvest LLC bought a new stake in shares of Neurocrine Biosciences during the third quarter worth $28,000. BluePath Capital Management LLC bought a new position in Neurocrine Biosciences in the third quarter valued at about $35,000. Sunbelt Securities Inc. boosted its stake in shares of Neurocrine Biosciences by 34.3% during the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock valued at $37,000 after purchasing an additional 83 shares in the last quarter. Fifth Third Bancorp grew its holdings in shares of Neurocrine Biosciences by 51.3% during the third quarter. Fifth Third Bancorp now owns 622 shares of the company’s stock worth $70,000 after purchasing an additional 211 shares during the last quarter. Finally, C M Bidwell & Associates Ltd. acquired a new position in shares of Neurocrine Biosciences in the third quarter valued at approximately $100,000. 92.59% of the stock is owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Eiry Roberts sold 1,457 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $140.79, for a total value of $205,131.03. Following the completion of the sale, the insider now owns 20,832 shares of the company’s stock, valued at approximately $2,932,937.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Neurocrine Biosciences news, insider David W. Boyer sold 456 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total transaction of $64,733.76. Following the sale, the insider now owns 4,894 shares of the company’s stock, valued at approximately $694,752.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eiry Roberts sold 1,457 shares of Neurocrine Biosciences stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $140.79, for a total value of $205,131.03. Following the completion of the transaction, the insider now owns 20,832 shares of the company’s stock, valued at $2,932,937.28. The disclosure for this sale can be found here. Insiders have sold a total of 186,994 shares of company stock worth $25,806,409 over the last ninety days. 4.40% of the stock is currently owned by company insiders.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $140.09 on Wednesday. The stock has a market capitalization of $13.94 billion, a price-to-earnings ratio of 57.89 and a beta of 0.25. The business’s fifty day moving average is $136.34 and its 200-day moving average is $127.54. Neurocrine Biosciences, Inc. has a one year low of $89.04 and a one year high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The company’s revenue was up 25.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.88 EPS. Research analysts expect that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on NBIX. Barclays boosted their target price on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Finally, Mizuho upped their price objective on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average target price of $139.67.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.